Zura Bio (NASDAQ:ZURA) Given Buy Rating at Guggenheim

Zura Bio (NASDAQ:ZURA)‘s stock had its “buy” rating reissued by Guggenheim in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Tuesday, December 24th. Chardan Capital cut their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.00.

Zura Bio Trading Up 1.5 %

Shares of ZURA stock opened at $1.36 on Wednesday. Zura Bio has a 12 month low of $1.07 and a 12 month high of $6.35. The firm has a fifty day moving average price of $1.47 and a 200 day moving average price of $2.75.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter. On average, sell-side analysts expect that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in Zura Bio by 70.6% during the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after acquiring an additional 377,545 shares during the last quarter. Barclays PLC increased its holdings in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after purchasing an additional 56,757 shares during the period. Rhumbline Advisers raised its stake in shares of Zura Bio by 37.3% during the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after purchasing an additional 10,231 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Zura Bio during the third quarter worth $71,000. Finally, Braidwell LP purchased a new position in Zura Bio in the 3rd quarter valued at $10,040,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.